In this double-blind , placebo-controlled , randomized , multinational phase III trial , 1,144 patients with human epidermal growth factor receptor 2 ( HER2 ) - negative breast cancer who had not received cytotoxic chemotherapy in the advanced setting were randomly assigned at a two-to-one ratio to receive docetaxel 75 mg/m ( 2 ) plus ramucirumab 10 mg/kg or docetaxel 75 mg/m ( 2 ) plus placebo once every 3 weeks .